Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.

In conclusion, promiximab-DUBA is highly efficacious in small cell lung cancer xenograft models, and provides a new immunotherapy approach for SCLC. PMID: 29435172 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29435172?dopt=Abstract

Source: Oncotarget - February 14, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research